Citius Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2019 Annual Meeting of Stockholders held by Citius Pharmaceuticals, Inc. on February 13, 2019. The company is incorporated in Nevada and maintains its principal executive offices in Cranford, NJ.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and voting results.
Material Changes and Voting Results
Stockholders elected seven members to the Board of Directors for a term expiring in 2020. All nominees received unanimous support with zero votes against:
- Myron Holubiak: 10,324,210 For
- Leonard Mazur: 10,330,926 For
- Suren Dutia: 10,331,077 For
- Carol Webb: 10,331,132 For
- Dr. William Kane: 10,331,138 For
- Howard Safir: 10,330,876 For
- Dr. Eugene Holuka: 10,331,138 For
Additionally, stockholders approved the following on a non-binding advisory basis and by ratification:
- Executive Compensation: 10,214,768 For, 108,000 Against, 18,295 Abstaining.
- Independent Auditor: Ratified Wolf & Company, P.C. for the fiscal year ending September 30, 2019. Vote: 14,003,089 For, 29,797 Against, 38,753 Abstaining.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the composition of the newly elected Board of Directors and their terms.
- Confirm the appointment of Wolf & Company, P.C. as the independent auditor for the fiscal year ending September 30, 2019.
- Review the proxy statement for details regarding the executive compensation package that received advisory approval.
- Note the significant number of broker non-votes (3,730,576) on the executive compensation proposal.